Active surveillance; A reasonable management alternative for patients with prostate cancer

The Miami experience

Mark S. Soloway, Cynthia T. Soloway, Steve Williams, Rajinikanth Ayyathurai, Bruce Kava, Murugesan Manoharan

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Study Type - Therapy (individual cohort study) Level of Evidence 2b OBJECTIVE: To examine the outcome of patients diagnosed with 'low-risk' prostate cancer managed by active surveillance (AS). PATIENTS AND METHODS: In all, 157 men with localized prostate cancer were followed on AS. The inclusion criteria for AS included: Gleason score of ≤6, a serum prostate-specific antigen (PSA) level of ≤15 ng/mL, stage ≤T2, low-volume disease and >12 months of follow-up. The follow-up was rigorous, with PSA tests and a digital rectal examination every 3 months for 2 years, and a repeat biopsy 6-12 months after the initial diagnosis and yearly when indicated. Continuance of AS was based on the PSA doubling time, re-biopsy score, Gleason score, tumour volume, stage progression and patient preference. RESULTS: In all 99 patients met the inclusion criteria; their mean age at diagnosis was 66 years, their mean PSA level 5.77 ng/mL and the mean follow-up 45.3 months. On initial repeat biopsy, 63% had no cancer and 34% had a Gleason sum of ≤6. Eight patients were treated (three with hormones; five with curative intent); two had radical prostatectomy (one had pT2c pNO Gleason 7 disease); three had radiotherapy. The probability is that 85% would remain treatment-free at 5 years; no patient died from prostate cancer. The PSA doubling time and clinical stage at diagnosis were predictive of progression. CONCLUSION: Patients who are followed on AS must be selected using narrowly defined inclusion criteria and closely followed with a standard regimen of PSA testing, digital rectal examination and repeat biopsy.

Original languageEnglish
Pages (from-to)165-169
Number of pages5
JournalBJU International
Volume101
Issue number2
DOIs
StatePublished - Jan 1 2008

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Biopsy
Digital Rectal Examination
Neoplasm Grading
Patient Preference
Prostatectomy
Tumor Burden
Cohort Studies
Radiotherapy
Hormones
Therapeutics
Serum
Neoplasms

Keywords

  • Active surveillance
  • Follow-up protocol
  • Progression
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Active surveillance; A reasonable management alternative for patients with prostate cancer : The Miami experience. / Soloway, Mark S.; Soloway, Cynthia T.; Williams, Steve; Ayyathurai, Rajinikanth; Kava, Bruce; Manoharan, Murugesan.

In: BJU International, Vol. 101, No. 2, 01.01.2008, p. 165-169.

Research output: Contribution to journalArticle

Soloway, Mark S. ; Soloway, Cynthia T. ; Williams, Steve ; Ayyathurai, Rajinikanth ; Kava, Bruce ; Manoharan, Murugesan. / Active surveillance; A reasonable management alternative for patients with prostate cancer : The Miami experience. In: BJU International. 2008 ; Vol. 101, No. 2. pp. 165-169.
@article{8b7f8733b4c6462bbf5c150da75241c0,
title = "Active surveillance; A reasonable management alternative for patients with prostate cancer: The Miami experience",
abstract = "Study Type - Therapy (individual cohort study) Level of Evidence 2b OBJECTIVE: To examine the outcome of patients diagnosed with 'low-risk' prostate cancer managed by active surveillance (AS). PATIENTS AND METHODS: In all, 157 men with localized prostate cancer were followed on AS. The inclusion criteria for AS included: Gleason score of ≤6, a serum prostate-specific antigen (PSA) level of ≤15 ng/mL, stage ≤T2, low-volume disease and >12 months of follow-up. The follow-up was rigorous, with PSA tests and a digital rectal examination every 3 months for 2 years, and a repeat biopsy 6-12 months after the initial diagnosis and yearly when indicated. Continuance of AS was based on the PSA doubling time, re-biopsy score, Gleason score, tumour volume, stage progression and patient preference. RESULTS: In all 99 patients met the inclusion criteria; their mean age at diagnosis was 66 years, their mean PSA level 5.77 ng/mL and the mean follow-up 45.3 months. On initial repeat biopsy, 63{\%} had no cancer and 34{\%} had a Gleason sum of ≤6. Eight patients were treated (three with hormones; five with curative intent); two had radical prostatectomy (one had pT2c pNO Gleason 7 disease); three had radiotherapy. The probability is that 85{\%} would remain treatment-free at 5 years; no patient died from prostate cancer. The PSA doubling time and clinical stage at diagnosis were predictive of progression. CONCLUSION: Patients who are followed on AS must be selected using narrowly defined inclusion criteria and closely followed with a standard regimen of PSA testing, digital rectal examination and repeat biopsy.",
keywords = "Active surveillance, Follow-up protocol, Progression, Prostate cancer",
author = "Soloway, {Mark S.} and Soloway, {Cynthia T.} and Steve Williams and Rajinikanth Ayyathurai and Bruce Kava and Murugesan Manoharan",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1464-410X.2007.07190.x",
language = "English",
volume = "101",
pages = "165--169",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Active surveillance; A reasonable management alternative for patients with prostate cancer

T2 - The Miami experience

AU - Soloway, Mark S.

AU - Soloway, Cynthia T.

AU - Williams, Steve

AU - Ayyathurai, Rajinikanth

AU - Kava, Bruce

AU - Manoharan, Murugesan

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Study Type - Therapy (individual cohort study) Level of Evidence 2b OBJECTIVE: To examine the outcome of patients diagnosed with 'low-risk' prostate cancer managed by active surveillance (AS). PATIENTS AND METHODS: In all, 157 men with localized prostate cancer were followed on AS. The inclusion criteria for AS included: Gleason score of ≤6, a serum prostate-specific antigen (PSA) level of ≤15 ng/mL, stage ≤T2, low-volume disease and >12 months of follow-up. The follow-up was rigorous, with PSA tests and a digital rectal examination every 3 months for 2 years, and a repeat biopsy 6-12 months after the initial diagnosis and yearly when indicated. Continuance of AS was based on the PSA doubling time, re-biopsy score, Gleason score, tumour volume, stage progression and patient preference. RESULTS: In all 99 patients met the inclusion criteria; their mean age at diagnosis was 66 years, their mean PSA level 5.77 ng/mL and the mean follow-up 45.3 months. On initial repeat biopsy, 63% had no cancer and 34% had a Gleason sum of ≤6. Eight patients were treated (three with hormones; five with curative intent); two had radical prostatectomy (one had pT2c pNO Gleason 7 disease); three had radiotherapy. The probability is that 85% would remain treatment-free at 5 years; no patient died from prostate cancer. The PSA doubling time and clinical stage at diagnosis were predictive of progression. CONCLUSION: Patients who are followed on AS must be selected using narrowly defined inclusion criteria and closely followed with a standard regimen of PSA testing, digital rectal examination and repeat biopsy.

AB - Study Type - Therapy (individual cohort study) Level of Evidence 2b OBJECTIVE: To examine the outcome of patients diagnosed with 'low-risk' prostate cancer managed by active surveillance (AS). PATIENTS AND METHODS: In all, 157 men with localized prostate cancer were followed on AS. The inclusion criteria for AS included: Gleason score of ≤6, a serum prostate-specific antigen (PSA) level of ≤15 ng/mL, stage ≤T2, low-volume disease and >12 months of follow-up. The follow-up was rigorous, with PSA tests and a digital rectal examination every 3 months for 2 years, and a repeat biopsy 6-12 months after the initial diagnosis and yearly when indicated. Continuance of AS was based on the PSA doubling time, re-biopsy score, Gleason score, tumour volume, stage progression and patient preference. RESULTS: In all 99 patients met the inclusion criteria; their mean age at diagnosis was 66 years, their mean PSA level 5.77 ng/mL and the mean follow-up 45.3 months. On initial repeat biopsy, 63% had no cancer and 34% had a Gleason sum of ≤6. Eight patients were treated (three with hormones; five with curative intent); two had radical prostatectomy (one had pT2c pNO Gleason 7 disease); three had radiotherapy. The probability is that 85% would remain treatment-free at 5 years; no patient died from prostate cancer. The PSA doubling time and clinical stage at diagnosis were predictive of progression. CONCLUSION: Patients who are followed on AS must be selected using narrowly defined inclusion criteria and closely followed with a standard regimen of PSA testing, digital rectal examination and repeat biopsy.

KW - Active surveillance

KW - Follow-up protocol

KW - Progression

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=37349047020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349047020&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2007.07190.x

DO - 10.1111/j.1464-410X.2007.07190.x

M3 - Article

VL - 101

SP - 165

EP - 169

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -